Close

Immunogen, Inc. (IMGN) Tops Q3 EPS by 13c; Sees Wider FY13 Loss

April 26, 2013 6:33 AM EDT
Immunogen, Inc. (NASDAQ: IMGN) reported Q3 EPS of ($0.02), $0.13 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $25 million versus the consensus estimate of $11.94 million.

ImmunoGen now expects its net loss for its fiscal year ending June 30, 2013 to be between $76 million to $80 million, its net cash used in operations to be between $65 million to $69 million, and its capital expenditures to be between $4 million to $5 million. Cash and cash equivalents at June 30, 2013 are anticipated to be between $186 million to $190 million.

This compares with previous guidance, issued in January 2013, of a projected net loss between $70 million to $74 million, net cash used in operations of between $78 million to $82 million, comparable capital expenditures, and ending the fiscal year on June 30, 2013 with cash and cash equivalents between $172 million to $176 million.

For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings